Dropout rates from the LT waiting list are relatively high, approximately 15% to 30% at 1 year from baseline.15 Several patient characteristics are associated with increased risk of waiting list dropout for patients with HCC, including MELD score at baseline,17,18,19 the presence of multifocal HCC, larger tumor size, and high peak AFP level.20,21,22 While these liver- and tumor-related variables are clearly associated with wait-list outcomes, to our knowledge, no prior studies have specifically examined the association of insurance type on outcomes on the LT waiting list. The gene discussed is AFP; the disease is hepatocellular carcinoma.